Hot topics in perioperative immune combination therapy for liver cancer / 中华肝胆外科杂志
Chinese Journal of Hepatobiliary Surgery
; (12): 1-4, 2023.
Article
в Zh
| WPRIM
| ID: wpr-993272
Ответственная библиотека:
WPRO
ABSTRACT
Most patients with primary hepatocellular carcinoma (HCC) are already in advanced stage when they are diagnosed, with a short survival period and an extremely poor prognosis. HCC seriously threatens the life and health of Chinese people. In recent years, breakthroughs have been made in systemic treatment of HCC, especially in immunotherapy represented by immune checkpoint inhibitors, which has broken the single therapy situation of molecular targeted drugs. And the strategy of immunotherapy combined with anti-angiogenic therapy has shown superiority and profoundly changed the treatment strategy of HCC. This article focuses on several hotspots of immune checkpoint inhibitors combined with anti-angiogenic targeted drugs in the perioperative scenario of HCC, and takes stock of the latest research progress of immunotherapy combined with anti-angiogenic drugs regimens in the perioperative application of HCC.
Полный текст:
1
База данных:
WPRIM
Язык:
Zh
Журнал:
Chinese Journal of Hepatobiliary Surgery
Год:
2023
Тип:
Article